

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**New Horizon Health Limited**

**諾輝健康**

(Joint Provisional Liquidators Appointed)

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6606)

**ADDITIONAL RESUMPTION GUIDANCE  
AND  
UPDATE ON THE WINDING UP PETITION HEARING**

This announcement is made by New Horizon Health Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) pursuant to Rule 13.09(2) (a) and Rule 13.24A of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

**ADDITIONAL RESUMPTION GUIDANCE**

Reference is made to (i) the announcement of the Company dated May 28, 2024 in relation to the resumption guidance from the Stock Exchange; (ii) the announcement of the Company dated January 9, 2025 in relation to the additional resumption guidance from the Stock Exchange; and (iii) the announcement of the Company dated March 10, 2025 in relation to the modified and additional resumption guidance from the Stock Exchange. Unless otherwise stated, capitalized terms used in this announcement shall bear the same meanings as those defined in the announcements.

On August 12, 2025, the Company received a letter from the Stock Exchange, in which the Stock Exchange notifies the Company of the following additional resumption guidance (the “**Third Additional Resumption Guidance**”, together with the Initial Resumption Guidance, the Additional Resumption Guidance, the Second Additional Resumption Guidance and the Modified Resumption Guidance, collectively referred to as the “**Resumption Guidance**”) for the Company:

- have the appointment of the liquidators discharged; and
- re-comply with Rules 3.10(1), 3.25, 3.27A and 13.92 of the Listing Rules.

The Stock Exchange states that the Company must remedy the issues causing its trading suspension and fully comply with the Listing Rules to the Stock Exchange’s satisfaction before trading in its securities is allowed to resume. For this purpose, the Company has the primary responsibility to devise its action plan for resumption. The Stock Exchange indicates that it may modify or supplement the Resumption Guidance if the Company’s situation changes.

#### **UPDATE ON THE WINDING UP PETITION HEARING**

Reference is made to (i) the announcement of the Company dated July 4, 2025 in relation to the JPL Application and Petition; (ii) the announcement of the Company dated August 1, 2025 in relation to the application for appointment of JPLs; and (iii) the announcement of the Company dated August 8, 2025 in relation to the appointment of JPLs. Unless otherwise stated, capitalized terms used in this announcement shall bear the same meanings as those defined in the announcements.

The hearing of the Petition will take place on November 14, 2025 at 10:00 a.m. (Cayman time) before the Grand Court.

Further announcements will be made as soon as practicable to update the Shareholders on the development of the Petition.

## **CONTINUED SUSPENSION OF TRADING**

Trading in the Company's shares on the Stock Exchange has been suspended since March 28, 2024, and will remain suspended until further notice.

**Shareholders and potential investors should exercise caution when dealing in the securities of the Company.**

For and on behalf of  
**New Horizon Health Limited**  
(Joint Provisional Liquidators Appointed)  
**Mr. Lai Wing Lun (Johnathan),**  
**Mr. Osman Mohammed Arab**  
**and Mr. Martin Nicholas John Trott**  
Joint Provisional Liquidators  
Acting as agents without personal liabilities

Hong Kong, August 12, 2025

*As at the date of this announcement, the Board comprises Mr. Naxin YAO as Chairman and non-executive Director, Dr. Yiyu CHEN as executive Director, and Mr. Danke YU and Dr. Yang WANG as independent non-executive Directors. All powers of the Directors are suspended upon appointment of the Joint Provisional Liquidators pursuant to the Order of the Grand Court of the Cayman Islands dated 6 August 2025.*

*The assets and affairs of the Company are being managed by the Joint Provisional Liquidators who act as the agents of the Company only and without personal liabilities.*